Early Clinical Outcome of Perceval Aortic Valve Implantation in Townsville, Australia.
Source: PubMed, NCBI / U.S. National Library of Medicine
Sutureless aortic valve replacement (AVR) using the Perceval valve has emerged as a valuable alternative to conventional surgical valves, offering procedural and recovery advantages. This study presents 30-day clinical outcomes from a single-centre Australian experience with Perceval AVR. Between September 2014 and June 2023, a total of 297 patients underwent sutureless AVR with the Perceval valve (Corcym) across two hospitals in Townsville, Australia. Of these, 117 patients underwent AVR combined with concomitant procedures. This is a retrospective cross-sectional analysis of perioperative data and 30-day postoperative outcomes. The mean patient age was 72.9 years, and 64.1% were female. A minimally invasive mini-sternotomy approach was used in 27 patients (9.1%). Large or extra-large Perceval valves were implanted in 204 patients (68.7%). For isolated AVR, the median aortic cross-clamp (ACC) time and cardiopulmonary bypass (CPB) time were 54.9 minutes and 72.4 minutes, respectively. In combined procedures, median ACC and CPB times were 69.9 and 94.7 minutes, respectively. Intraoperative transesophageal echocardiography confirmed the absence of paravalvular leak (PVL) in 291 patients (98%), with trivial PVL observed in six patients (2%). At 30-day follow-up, no PVL was detected in any patient. The mean intensive care unit stay was 2.3 days, and the average hospital stay was 6.8 days. Permanent pacemaker implantation was required in 19 patients (6%), and cardiac mortality wit
Abstract
Sutureless aortic valve replacement (AVR) using the Perceval valve has emerged as a valuable alternative to conventional surgical valves, offering procedural and recovery advantages. This study presents 30-day clinical outcomes from a single-centre Australian experience with Perceval AVR. Between September 2014 and June 2023, a total of 297 patients underwent sutureless AVR with the Perceval valve (Corcym) across two hospitals in Townsville, Australia. Of these, 117 patients underwent AVR combined with concomitant procedures. This is a retrospective cross-sectional analysis of perioperative data and 30-day postoperative outcomes. The mean patient age was 72.9 years, and 64.1% were female. A minimally invasive mini-sternotomy approach was used in 27 patients (9.1%). Large or extra-large Perceval valves were implanted in 204 patients (68.7%). For isolated AVR, the median aortic cross-clamp (ACC) time and cardiopulmonary bypass (CPB) time were 54.9 minutes and 72.4 minutes, respectively. In combined procedures, median ACC and CPB times were 69.9 and 94.7 minutes, respectively. Intraoperative transesophageal echocardiography confirmed the absence of paravalvular leak (PVL) in 291 patients (98%), with trivial PVL observed in six patients (2%). At 30-day follow-up, no PVL was detected in any patient. The mean intensive care unit stay was 2.3 days, and the average hospital stay was 6.8 days. Permanent pacemaker implantation was required in 19 patients (6%), and cardiac mortality within 30 days occurred in two patients (0.6%). Two-year survival, based on Kaplan-Meier analysis, was 89.2%. This study demonstrates excellent early outcomes with Perceval sutureless AVR, including high procedural success, minimal PVL, and low postoperative complication rates. These results support Perceval as a safe and effective alternative to conventional bioprosthetic valves, particularly in high-risk patients where minimising CPB and ACC time is advantageous.